Document is current
Any future updates will be listed below
-
Authors
Rabl, Miriam
Zullo, Leonardo
Lewczuk, Piotr
Kornhuber, Johannes
Karikari, Thomas K.
Blennow, Kaj
Zetterberg, Henrik
Bavato, Francesco
Quednow, Boris B.
Seifritz, Erich
von Gunten, Armin
Clark, Christopher
Popp, Julius
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_141179)
Synapsis Foundation - Dementia Research Switzerland (2017-PI01)
- License Information
-
More Information
Article History
Received: 17 March 2024
Accepted: 9 July 2024
First Online: 25 July 2024
Declarations
:
: The study was conducted in accordance with applicable laws and regulations, including the International Conference on Harmonization, Guideline for Good Clinical Practice [], and the ethical principles from the Declaration of Helsinki []. The study was approved by the local ethics committee of canton Vaud, Switzerland (No. 171/2013). Prior to inclusion, written informed consent was obtained from all participants.
: PL received consultation and/or lecture honoraria from IBL International, Fujirebio Europe, AJ Roboscreen, Biogen, and Roche. KB has served as a consultant, at advisory boards, or at data monitoring committees for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). CC received consultation and speaker honoraria from OM Pharma Suisse. MR received speaker honoraria from OM Pharma Suisse. JP received consultation and speaker honoraria from Nestle Institute of Health Sciences, Innovation Campus EPFL, Ono Pharma, Lilly, Roche, Eisai, Schwabe Pharma, OM Pharma Suisse and from Fujirebio Europe. The other authors declare no potential conflicts of interest.
